Single Ascending Dose, Multiple Ascending Dose, Food Effect Study With AP31969

NCT06066099 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2025-07-14

No results posted yet for this study

Summary

The primary objective of the study is to evaluate the safety and tolerability of single doses (Part A) and multiple doses (Part B) of AP31969 in healthy participants.

Conditions

  • Healthy Volunteers

Interventions

DRUG

AP31969

Oral tablets

DRUG

Placebo

Oral tablets

Sponsors & Collaborators

  • Acesion Pharma

    lead INDUSTRY

Principal Investigators

  • Director Clinical Operations · Acesion Pharma

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-04
Primary Completion
2025-03-14
Completion
2025-03-14

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06066099 on ClinicalTrials.gov